Hone Health vs Peter MD: TRT Platforms Compared
Hone Health and Peter MD are both TRT-first telehealth platforms, but they take different approaches: Hone leans heavily on biomarker testing and women's hormone support; Peter MD is a men-only program that bundles TRT with GLP-1-based weight loss.
Reader-supported, we may earn a commission through links on this site. Rankings are editorially independent. Disclosure · Methodology
Hone Health and Peter MD are both men's health platforms with a strong TRT focus, but they approach the category differently. Hone Health is a TRT-first platform that has expanded into adjacent categories (weight loss, sexual health, cognitive health) and is known for its comprehensive diagnostic baseline and physician-led protocol. Peter MD is a broader men's health platform that covers TRT, ED, hair loss, and weight management, with a more accessible entry price.
The key differentiator is clinical depth versus accessibility. Hone Health's diagnostic protocol is more rigorous — it requires a comprehensive hormone panel before prescribing and includes regular follow-up labs. Peter MD's entry price is lower and the onboarding is faster, but the clinical oversight is lighter. For men who want a thorough diagnostic baseline and a physician-led TRT protocol, Hone Health is the stronger choice. For men who want quick access at a lower price point, Peter MD is more accessible.
Hone Health
Hormone optimisation platform with real biomarker testing and physician-guided protocols, for men and women.
Peter MD
Affordable men's health clinic specialised in TRT and weight loss with transparent pricing.
Side-by-Side Comparison
| Attribute | Hone Health | Peter MD |
|---|---|---|
| Program Fee | From $25/mo (membership) | Included in monthly plan |
| Medication From | From $25 – $399/mo | From $79 – $349/mo |
| Editor Score | 4.4 / 5 | 4.4 / 5 |
| Primary Category | TRT & Men's Hormones | TRT & Men's Hormones |
| FDA Brand-Name Access | Compounded only | Compounded only |
| Compounded Options | 1 compounds | 2 compounds |
| Adjacent Categories | TRT & Men's Hormones, Women's Health & HRT | TRT & Men's Hormones, GLP-1 Weight Loss, Erectile Dysfunction, Hair Loss, Peptide Therapy, Primary Care |
What the Studies Actually Show
Testosterone reference ranges and clinical recommendations below are drawn from the 2018 Endocrine Society Clinical Practice Guideline (JCEM) and the AUA 2018 testosterone deficiency guideline. Both platforms operate within the standard of care; differences are in panel breadth, dosing forms, and add-on services rather than in the underlying medicine.
| Endpoint | Hone Health | Peter MD |
|---|---|---|
| Adult male total testosterone reference range (Endocrine Society)1 | 264–916 ng/dL is the typical reference range; treatment is generally considered when total T is consistently below 264 ng/dL with symptoms | Same |
| Recommended baseline biomarker panel1,2 | Total T, free T, SHBG, LH, FSH, estradiol, PSA (men over 40), CBC, CMP, lipids, hematocrit | Total T, free T, estradiol, hematocrit, PSA, CMP |
| Hematocrit monitoring (key safety endpoint)2 | Required at baseline and at follow-up testing; treatment paused if HCT >54% | Required at baseline and quarterly |
| Major TRT cardiovascular safety evidence3 | TRAVERSE trial (2023): TRT was non-inferior to placebo for major adverse cardiovascular events in middle-aged and older men with hypogonadism and elevated CV risk | Same |
| Women's hormone support | Yes, Hone+ for women includes thyroid, estrogen, progesterone, DHEA testing | No (men-only) |
| Bundled GLP-1 weight loss | Available as add-on | Bundled into core subscription |
Note on recommended baseline biomarker panelBoth panels meet the AUA minimum. Hone's panel is broader, which helps detect secondary causes of low T (e.g., elevated SHBG, hypogonadotropic hypogonadism).
The Verdict
Choose Hone Health for the data-driven protocol, broader biomarker panel, and the option to include women's hormone care. Choose Peter MD if you want a single male-focused subscription that handles both TRT and GLP-1 weight loss.
Frequently Asked Questions
- Endocrine Society Clinical Practice Guideline (Testosterone Therapy in Men with Hypogonadism, 2018) · Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018;103(5):1715–1744.
- AUA Guideline. Evaluation and Management of Testosterone Deficiency (2018) · Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol 2018;200(2):423–432.
- TRAVERSE Trial. NEJM 2023 · Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med 2023;389:107–117.
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.